Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466855 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
A Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01466855: Clinical Trial Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT01466855 is a Early Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 36 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01466855, a Early Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC). The goals of this study are: * To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery) * To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC * To assess visual pathway function before and after the study therapy * To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery
Interventions
- DRUG Intra-Ophthalmic Artery Topotecan Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-10 |
| Phase | Early Phase 1 |
Why NCT01466855 stopped before completion
NCT01466855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Intra-Ophthalmic Artery Topotecan Infusion is the first listed.
NCT01466855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01466855 about?
NCT01466855 is a clinical study titled "A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma". This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC). The goals of this study are: * To find out if topotecan is an effective treatment...
What is the current status of trial NCT01466855?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2011-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01466855?
The interventions under investigation include: Intra-Ophthalmic Artery Topotecan Infusion (DRUG).
Who is sponsoring clinical trial NCT01466855?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01466855's enrollment target sits among peer trials
36 712th of 2000 higher than 1,266 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia